Immatics
72 articles about Immatics
-
Immatics Announces Full Year 2023 Financial Results and Corporate Update
3/21/2024
Immatics N.V. provided a business update and reported financial results for the quarter and full year ended December 31, 2023.
-
Immatics Announces Pricing of $175 Million Public Offering
1/18/2024
Immatics N.V. announced the pricing of an underwritten public offering of 15,925,000 ordinary shares at a public offering price of $11.00 per share.
-
Immatics Announces Proposed Public Offering - Jan 17, 2024
1/17/2024
Immatics N.V., a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, announced the commencement of an underwritten public offering of its ordinary shares.
-
Immatics Announces Third Quarter 2023 Financial Results and Business Update
11/14/2023
Immatics N.V., a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, provided a business update and reported financial results for the quarter ended September 30, 2023.
-
Immatics Reports Interim Clinical Data from ACTengine® IMA203 and IMA203CD8 TCR-T Monotherapies Targeting PRAME in an Ongoing Phase 1 Trial
11/8/2023
IMA203 data with focus on melanoma patients presented at the International Congress of the Society for Melanoma Research , November 8
-
Immatics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ACTengine® IMA203 TCR-T Monotherapy
10/24/2023
Immatics N.V. announced that its IMA203 TCR-T program has received Regenerative Medicine Advanced Therapy designation from the FDA Center for Biologics Evaluation and Research in multiple relapsed and/or refractory HLA-A*02:01-positive and PRAME-expressing cancers, including cutaneous melanoma, uveal melanoma, endometrial carcinoma, synovial sarcoma, and ovarian cancer.
-
The collaboration, which includes an upfront payment of $120 million to Immatics, pairs Moderna’s mRNA technology with Immatics’ T-cell receptor platform for cancer treatment.
-
Immatics Initiates Phase 1/2 Clinical Trial to Evaluate PRAME TCR Bispecific IMA402 in Patients with Advanced Solid Tumors
8/10/2023
Immatics N.V., a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, announced the initiation of a Phase 1/2 clinical trial with its proprietary Bispecific T cell engaging receptor IMA402.
-
GSK has pulled out of its partnership focused on developing T-cell receptor therapeutics for solid tumors with Immatics, the German biotech revealed in its Q3 financial results published Thursday.
-
Immatics Announces Third Quarter 2022 Financial Results and Business Update
11/17/2022
Immatics N.V. provided a business update and reported financial results for the quarter ended September 30, 2022.
-
Immatics announced plans to raise about $110 million in a common stock offering following the release of promising early-stage data that supports its ACTengine technology platform.
-
Immatics Presents Comprehensive Preclinical Data Set for TCR Bispecific Candidate IMA402 Targeting PRAME at European Society for Medical Oncology (ESMO) Congress 2022
9/10/2022
Immatics N.V. announced a comprehensive preclinical data set for its T cell engaging receptor product candidate IMA402 at the European Society for Medical Oncology Congress 2022 held in Paris, France, from September 9 to 13, 2022.
-
89bio presented positive data for pegozafermin in SHTG, Tonix enrolled its first patient with Long COVID for TNX-102, Belite enrolled patients with STGD1 and more clinical trial news.
-
The combination of Opdivo plus Yervoy in addition to chemotherapy demonstrated additional benefits in patient populations who usually have poor prognoses.
-
Immatics Announces First Quarter 2022 Financial Results and Business Update
6/2/2022
Immatics N.V., a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, reported financial results and provided a business update for the quarter ended March 31, 2022.
-
Closing out the month of May, plenty of companies presented or announced clinical trial updates and news. Here’s a look.
-
Immatics Initiates Phase 1 Clinical Trial to Evaluate Lead TCR Bispecific IMA401 in Patients with Advanced Solid Tumors
5/10/2022
Immatics N.V., a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, announced the initiation of a Phase 1 clinical trial with its T cell engaging receptor IMA401 for patients with recurrent and/or refractory solid tumors.
-
Bristol Myers Squibb is dropping $920 million to acquire the exclusive global rights of Immatics' experimental cancer drug program, the companies announced Tuesday morning.
-
BioCopy AG and Immatics enter into a collaboration to characterize T cell receptor - peptide-HLA interactions
7/7/2021
BioCopy AG announces a collaboration with Immatics N.V. "Immatics" in the field of characterization of T cell receptors.
-
Immatics Announces Changes to its Board of Directors - May 26, 2021
5/26/2021
Tuebingen, Germany and Houston, Texas, May26, 2021 – Immatics N.V., a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, announced changes to its Board of Directors.